10-QPeriod: Q1 FY2021

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q1 Ended Mar 31, 2021

Filed April 30, 2021For Securities:VRTX

Summary

Vertex Pharmaceuticals reported strong revenue growth in the first quarter of 2021, with total revenues increasing by 14% year-over-year to $1.724 billion. This growth was primarily driven by the strong performance of TRIKAFTA/KAFTRIO, particularly its uptake in Europe, and continued solid performance in the U.S. Net income also saw a healthy increase of 8% to $653.1 million, or $2.49 per diluted share. The company continues to invest heavily in research and development, with a focus on expanding its pipeline beyond cystic fibrosis into areas like sickle cell disease, type 1 diabetes, and pain management. Significant upcoming expenditures include a $900 million upfront payment to CRISPR Therapeutics related to the CTX001 gene therapy collaboration. Financially, Vertex maintains a robust liquidity position with $6.9 billion in cash, cash equivalents, and marketable securities. The company also completed its $500 million share repurchase program during the quarter. While the company faces ongoing research and development uncertainties and the potential for significant future expenditures, its strong revenue growth, solid profitability, and healthy balance sheet position it well for continued investment in its pipeline and future growth.

Financial Highlights

48 data points
Beta

Revenue

$1.72B

88.8% Gross Margin

Net Income

$653.10M

37.9% Net Margin

EPS (Diluted)

$2.49

Total Assets

$12.12B

Cash & Equivalents

$6.30B

Free Cash Flow

$850.10M

Financial Statements
Beta
Revenue$1.72B
Cost of Revenue$192.30M
Gross Profit$1.53B
R&D Expenses$456.00M
SG&A Expenses$192.10M
Operating Expenses$836.50M
Operating Income$887.80M
Net Income$653.10M
EPS (Basic)$2.52
EPS (Diluted)$2.49
Shares Outstanding (Basic)259.40M
Shares Outstanding (Diluted)261.90M

Key Highlights

  • 1Total revenues increased by 14% to $1.724 billion for the three months ended March 31, 2021, compared to $1.515 billion for the same period in 2020.
  • 2Net income grew by 8% to $653.1 million ($2.49 per diluted share) for the three months ended March 31, 2021, from $602.8 million ($2.29 per diluted share) in the prior year.
  • 3Product revenues were driven by TRIKAFTA/KAFTRIO, which saw a 33% increase, while other CF products experienced declines as patients switched to the newer therapy.
  • 4The company is significantly expanding its pipeline, with ongoing clinical trials in areas beyond cystic fibrosis, including sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, and pain.
  • 5Vertex entered into an amended collaboration with CRISPR Therapeutics for CTX001, involving a $900 million upfront payment and a 60/40 profit/loss split, positioning Vertex to lead global development and commercialization.
  • 6The company maintained a strong liquidity position with $6.9 billion in cash, cash equivalents, and marketable securities as of March 31, 2021.
  • 7Research and development expenses increased by 2% to $456.0 million, reflecting continued investment in pipeline expansion and clinical trials.

Frequently Asked Questions

Vertex's revenue growth was primarily driven by the strong uptake of its triple combination therapy, TRIKAFTA/KAFTRIO, in Europe and its continued solid performance in the U.S. This led to a 14% increase in total revenues to $1.724 billion for the quarter.

Vertex is significantly investing in its research and development pipeline, not only to expand its cystic fibrosis (CF) franchise but also to develop transformative medicines for other serious diseases. Key areas of focus include gene therapies for sickle cell disease and beta thalassemia (in collaboration with CRISPR), as well as small molecule therapies for alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, and pain. This diversification aims to broaden the company's therapeutic reach and long-term growth potential.

Vertex has amended its collaboration with CRISPR Therapeutics for the CTX001 gene therapy program, agreeing to a $900 million upfront payment and a $200 million milestone payment upon regulatory approval. Under the new terms, Vertex will lead global development, manufacturing, and commercialization and will share 60% of net profits and losses. This signifies a significant investment to advance a potentially curative therapy for sickle cell disease and beta thalassemia.

Vertex maintains a strong financial position, ending the first quarter of 2021 with $6.9 billion in cash, cash equivalents, and marketable securities. The company generated $921.1 million in cash from operations and completed a $500 million share repurchase program, demonstrating healthy cash flow and a commitment to returning capital to shareholders while funding its extensive R&D initiatives.